Literature DB >> 4158436

A new acute phase protein elicited in mice by streptolysin O and other toxic or infectious agents.

R Rowen, M A Wiest.   

Abstract

A new acute phase plasma component has been found in mice exposed to certain toxic materials and pathogenic bacteria. The abnormal component, detected by immunodiffusion employing absorbed antiserum, was chiefly studied in plasma of streptolysin O-treated mice where it appears within 24 hours after intravenous administration of a sublethal dose of the toxin. The new factor is a protein having the electrophoretic mobility of a slow alpha2-globulin. It is devoid of lipid and separate from the streptolysin O inhibitory lipoprotein that is also induced by administration of the streptococcal toxin. The factor, moreover, appears clearly distinct from haptoglobin or C-reactive protein and seems to be a unique type of acute phase protein. Its partial purification by starch block electrophoresis is described. A number of toxic materials other than streptolysin O, i.e. saponin, Cl. welchii phospholipase C (alpha-toxin), and endotoxins, were found to elicit the abnormal protein in mice. Phospholipase A (Crotalus adamanteus venom) and staphylococcal alpha-toxin failed to cause its appearance. Plasma samples of mice acutely infected with Group A streptococci, Staphylococcus aureus or pneumococcus uniformly contained the abnormal component. The significance of this acute phase protein has been considered in relation to the streptolysin O inhibitor and to the acute phase proteins of other animal species. It has been suggested that production of the new component and of the streptolysin O inhibitor may be manifestations of a single process constituting a physiological response to a variety of deleterious agents.

Entities:  

Mesh:

Substances:

Year:  1965        PMID: 4158436      PMCID: PMC2138079          DOI: 10.1084/jem.122.3.547

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  ABNORMAL SERUM COMPONENTS AFTER ESCHERICHIA COLI ENDOTOXIN ADMINISTRATION TO MALE AND FEMALE RATS.

Authors:  D J LAWFORD; R G WHITE
Journal:  Nature       Date:  1964-02-15       Impact factor: 49.962

2.  VERTEBRATE DISTRIBUTION OF SERUM CERULOPLASMIN AND SIALIC ACID AND THE EFFECTS OF PREGNANCY.

Authors:  U S SEAL
Journal:  Comp Biochem Physiol       Date:  1964-10

3.  Isolation and composition of staphylococcal alpha toxin.

Authors:  A W BERNHEIMER; L L SCHWARTZ
Journal:  J Gen Microbiol       Date:  1963-03

4.  The toxic action of preparations containing the oxygen-labile hemolysin of Streptococcus pyogenes. V. Mechanism of refractoriness to the lethal effect of the toxin.

Authors:  R ROWEN; A W BERNHEIMER
Journal:  J Immunol       Date:  1956-07       Impact factor: 5.422

5.  An Improved Medium for the Cultivation of Hemolytic Streptococcus.

Authors:  A W Bernheimer; W Gillman; G A Hottle; A M Pappenheimer
Journal:  J Bacteriol       Date:  1942-04       Impact factor: 3.490

6.  Zone electrophoresis in a starch supporting medium.

Authors:  H G KUNKEL; R J SLATER
Journal:  Proc Soc Exp Biol Med       Date:  1952-05

7.  INTERFERON-LIKE VIRAL INHIBITOR IN RABBITS AFTER INTRAVENOUS ADMINISTRATION OF ENDOTOXIN.

Authors:  M HO
Journal:  Science       Date:  1964-12-11       Impact factor: 47.728

8.  THE CARDIOTOXIC ACTION OF PREPARATIONS CONTAINING THE OXYGEN-LABILE HEMOLYSIN OF STREPTOCOCCUS PYOGENES : I. INCREASED SENSITIVITY OF THE ISOLATED FROG'S HEART TO REPEATED APPLICATION OF THE TOXIN.

Authors:  A W Bernheimer; G L Cantoni
Journal:  J Exp Med       Date:  1945-03-01       Impact factor: 14.307

9.  THE TOXIC ACTION OF PREPARATIONS CONTAINING THE OXYGEN-LABILE HEMOLYSIN OF STREPTOCOCCUS PYOGENES : III. INDUCTION IN MICE OF TEMPORARY RESISTANCE TO THE LETHAL EFFECT OF THE TOXIN.

Authors:  A W Bernheimer; G L Cantoni
Journal:  J Exp Med       Date:  1947-08-31       Impact factor: 14.307

10.  Changes produced in mouse plasma proteins by acute bacterial infections.

Authors:  C A WILLIAMS; C T WEMYSS
Journal:  J Exp Med       Date:  1961-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.